TG Therapeutics Stock Options Expiring on 7th of February
| TGTX Stock | USD 29.55 0.41 1.41% |
TG Therapeutics' latest option contracts expiring on February 7th 2025 are carrying combined implied volatility of 0.69 with a put-to-call open interest ratio of 0.79 over 40 outstanding agreements suggesting investors are buying slightly more calls than puts on contracts expiring on February 7th 2025. The total put volume is at 63.0, with calls trading at the volume of 2.0. This yields a 31.5 put-to-call volume ratio.
Open Interest Against February 7th 2025 Option Contracts
TG Therapeutics option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in TG Therapeutics' lending market. For example, when TG Therapeutics' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on TG Therapeutics, he or she must hedge the risk by shorting TG Therapeutics stock over its option's life.
2025-02-07
The chart above shows TG Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. TG Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for TG Therapeutics' option, there is no secondary market available for investors to trade.
TG Therapeutics Maximum Pain Price Across 2025-02-07 Option Contracts
Max pain occurs when TG Therapeutics' market makers reach a net positive position across all TG Therapeutics' options at a strike price where option holders stand to lose the most money. By contrast, TG Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
TG Therapeutics In The Money Call Balance
When TG Therapeutics' strike price is surpassing the current stock price, the option contract against TG Therapeutics stock is said to be in the money. When it comes to buying TG Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on TG Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
TGTX Current Options Market Mood
TG Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps TGTX Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most TG Therapeutics' options investors are not very successful. TG Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current TGTX contract
Base on the Rule 16, the options market is currently suggesting that TG Therapeutics will have an average daily up or down price movement of about 0.0431% per day over the life of the 2025-02-07 option contract. With TG Therapeutics trading at USD 29.55, that is roughly USD 0.0127. If you think that the market is fully incorporating TG Therapeutics' daily price movement you should consider buying TG Therapeutics options at the current volatility level of 0.69%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
TGTX |
TG Therapeutics Option Chain
When TG Therapeutics' strike price is surpassing the current stock price, the option contract against TG Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
TG Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on TGTX. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for TGTX. It also shows strike prices and maturity days for a TG Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | TGTX250207C00028500 | 6 | 28.5 | 2.2 - 2.85 | 3.4 | In |
Call | TGTX250207C00028000 | 5 | 28.0 | 2.5 - 3.0 | 2.43 | In |
Call | TGTX250207C00030000 | 5 | 30.0 | 1.5 - 1.9 | 2.1 | Out |
Call | TGTX250207C00029500 | 7 | 29.5 | 1.05 - 2.05 | 2.15 | Out |
Call | TGTX250207C00031500 | 2 | 31.5 | 0.85 - 1.5 | 1.25 | Out |
Call | TGTX250207C00031000 | 5 | 31.0 | 1.05 - 1.6 | 1.0 | Out |
Call | TGTX250207C00033000 | 7 | 33.0 | 0.5 - 1.15 | 1.45 | Out |
Call | TGTX250207C00032500 | 7 | 32.5 | 0.65 - 1.05 | 0.95 | Out |
Call | TGTX250207C00032000 | 7 | 32.0 | 0.75 - 1.4 | 1.5 | Out |
Call | TGTX250207C00035500 | 0 | 35.5 | 0.15 - 0.8 | 0.15 | |
Call | TGTX250207C00035000 | 10 | 35.0 | 0.2 - 1.0 | 1.05 | Out |
Call | TGTX250207C00034500 | 3 | 34.5 | 0.25 - 0.6 | 0.73 | Out |
Call | TGTX250207C00034000 | 2 | 34.0 | 0.35 - 1.15 | 3.2 | Out |
Call | TGTX250207C00037000 | 24 | 37.0 | 0.05 - 0.5 | 0.45 | Out |
Call | TGTX250207C00036500 | 0 | 36.5 | 0.05 - 0.6 | 0.05 | |
Call | TGTX250207C00036000 | 0 | 36.0 | 0.1 - 0.65 | 0.1 | |
Call | TGTX250207C00038000 | 0 | 38.0 | 0.0 - 0.35 | 0.35 | |
Call | TGTX250207C00039000 | 0 | 39.0 | 0.0 - 0.35 | 0.35 | |
Call | TGTX250207C00040000 | 0 | 40.0 | 0.0 - 0.35 | 0.35 | |
Call | TGTX250207C00045000 | 1 | 45.0 | 0.0 - 0.5 | 0.45 | Out |
Put | TGTX250207P00022500 | 10 | 22.5 | 0.0 - 0.3 | 0.16 | Out |
Put | TGTX250207P00025000 | 3 | 25.0 | 0.0 - 0.45 | 1.1 | Out |
Put | TGTX250207P00026000 | 10 | 26.0 | 0.0 - 0.75 | 1.48 | Out |
Put | TGTX250207P00028500 | 1 | 28.5 | 1.1 - 1.3 | 1.3 | Out |
Put | TGTX250207P00028000 | 2 | 28.0 | 0.95 - 1.3 | 1.2 | Out |
Put | TGTX250207P00027500 | 2 | 27.5 | 0.65 - 1.15 | 0.95 | Out |
Put | TGTX250207P00027000 | 30 | 27.0 | 0.0 - 0.95 | 1.88 | Out |
Put | TGTX250207P00030000 | 2 | 30.0 | 1.8 - 2.05 | 2.38 | In |
Put | TGTX250207P00029500 | 10 | 29.5 | 1.55 - 2.2 | 3.02 | Out |
Put | TGTX250207P00029000 | 2 | 29.0 | 1.35 - 1.6 | 2.83 | Out |
Put | TGTX250207P00035500 | 0 | 35.5 | 5.9 - 6.6 | 5.9 | In |
Put | TGTX250207P00035000 | 0 | 35.0 | 5.4 - 6.1 | 5.4 | In |
Put | TGTX250207P00034500 | 0 | 34.5 | 5.0 - 5.8 | 5.0 | In |
Put | TGTX250207P00037000 | 0 | 37.0 | 7.3 - 7.9 | 7.3 | In |
Put | TGTX250207P00036500 | 0 | 36.5 | 6.8 - 7.5 | 6.8 | In |
Put | TGTX250207P00036000 | 0 | 36.0 | 6.3 - 6.9 | 6.3 | In |
Put | TGTX250207P00038000 | 0 | 38.0 | 8.2 - 8.9 | 8.2 | In |
Put | TGTX250207P00039000 | 0 | 39.0 | 9.2 - 9.8 | 9.2 | In |
Put | TGTX250207P00040000 | 0 | 40.0 | 10.2 - 10.9 | 10.2 | In |
Put | TGTX250207P00045000 | 0 | 45.0 | 15.2 - 15.7 | 15.2 | In |
TG Therapeutics Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
TG Therapeutics Market Cap Over Time
Market Cap |
| Timeline |
TGTX Total Stockholder Equity
Total Stockholder Equity |
|
TG Therapeutics Corporate Executives
Elected by the shareholders, the TG Therapeutics' board of directors comprises two types of representatives: TG Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TGTX. The board's role is to monitor TG Therapeutics' management team and ensure that shareholders' interests are well served. TG Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TG Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.